國家衛生研究院 NHRI:Item 3990099045/4636

NHRI > National Institute of Cancer Research > Li-Tzong Chen > Conference Papers/Meeting Abstract > Item 3990099045/4636

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4636

Title:	An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer preliminary report
Authors:	Chao, Y;Li, CP;Chao, TY;Su, WC;Hsieh, RK;Wu, MF;Yeh, KH;Chen, LT;Cheng, AL
Contributors:	National Institute of Cancer Research
Abstract:	Background: To evaluate the response rate and safety of weekly paclitaxel (Taxol) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1:4 molar ratio) and leucovorin in patients with advanced gastric cancer. Methods: Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-hour infusion at a dose of 100 mg/m2 on days 1 and 8, and oral UFT 300 mg/m2/d plus leucovorin 90 mg/d were given starting from day 1 for 14 days, followed by a 7-day period without treatment, treatment repeated every 21 days. Results: From February 2003 to August 2004, 36 patients were enrolled. The median age was 60.8 years (range: 32 to 82). Among the 33 patients evaluable for tumor response, 1 achieved complete response and 12 partial response, with an overall response rate of 39.4% (95% CI: 11.2% to 53.0%). All 36 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 4.1 months and 7.7 months, respectively. Major grade 3-4 toxicities were neutropenia in 15 patients (41.7%) and diarrhea in 7 patients (19.4%). Treatment was discontinued due to treatment-related toxicities in 2 patients (5.6%). No patient died of treatment-related toxicities. Conclusions: We conclude that this paclitaxel-containing regimen is effective and well tolerated in the treatment of advanced gastric cancer.
Date:	2005-06
Relation:	Journal of Clinical Oncology. 2005 Jun;23(16):Abstract number 346S.
Link to:	http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/4156
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000230326602206
Appears in Collections:	[Li-Tzong Chen] Conference Papers/Meeting Abstract

Files in This Item:

There are no files associated with this item.

Loading...